Drugs / Rinotecan hydrochloride
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05684211 Background | Jan 2023 | colorectal cancer | Shanghai Celfuture Biotech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rinotecan hydrochloride | “Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W” NCT05684211 ↗ |
| Route | Intravenous | “intravenous titration” NCT05684211 ↗ |